Clinical Trials Browser

Phase 1/2 × Not yet recruiting × Triple Negative Breast Neoplasms × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07339176 2026-01-14

OP-NEU-101

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT05806385 2025-09-09

LOGIC

Phase 1/2 Not yet recruiting

36 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Phase 1/2 Not yet recruiting

12 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

59 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05821686 2025-02-12

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

10 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02802423 2025-02-07

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Phase 1/2 Not yet recruiting

44 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06078670 2023-10-12

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

96 enrolled

BreastGastrointestinal

Intestinal Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

NoCUT-BC

OP-NEU-101

LOGIC

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors